Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia.

Panetta JC, Yanishevski Y, Pui CH, Sandlund JT, Rubnitz J, Rivera GK, Ribeiro R, Evans WE, Relling MV.

Cancer Chemother Pharmacol. 2002 Nov;50(5):419-28. Epub 2002 Sep 24.

PMID:
12439601
2.

Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation.

Belkov VM, Krynetski EY, Schuetz JD, Yanishevski Y, Masson E, Mathew S, Raimondi S, Pui CH, Relling MV, Evans WE.

Blood. 1999 Mar 1;93(5):1643-50.

3.

In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.

Perentesis JP, Gunther R, Waurzyniak B, Yanishevski Y, Myers DE, Ek O, Messinger Y, Shao Y, Chelstrom LM, Schneider E, Evans WE, Uckun FM.

Clin Cancer Res. 1997 Dec;3(12 Pt 1):2217-27.

4.

In vivo toxicity and pharmacokinetic features of B43(Anti-CD19)-Genistein immunoconjugate.

Ek O, Yanishevski Y, Zeren T, Waurzyniak B, Gunther R, Chelstrom L, Chandan-Langlie M, Schneider E, Myers DE, Evans W, Uckun FM.

Leuk Lymphoma. 1998 Jul;30(3-4):389-94.

PMID:
9713969
5.

In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor.

Uckun FM, Narla RK, Zeren T, Yanishevski Y, Myers DE, Waurzyniak B, Ek O, Schneider E, Messinger Y, Chelstrom LM, Gunther R, Evans W.

Clin Cancer Res. 1998 May;4(5):1125-34.

6.

In vivo toxicity and pharmacokinetic features of B43 (anti-CD19)-genistein immunoconjugate in nonhuman primates.

Messinger Y, Yanishevski Y, Ek O, Zeren T, Waurzyniak B, Gunther R, Chelstrom L, Chandan-Langlie M, Schneider E, Myers DE, Evans W, Uckun FM.

Clin Cancer Res. 1998 Jan;4(1):165-70.

7.

Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia.

Relling MV, Yanishevski Y, Nemec J, Evans WE, Boyett JM, Behm FG, Pui CH.

Leukemia. 1998 Mar;12(3):346-52.

PMID:
9529129
8.
9.
10.

In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin.

Waurzyniak B, Schneider EA, Tumer N, Yanishevski Y, Gunther R, Chelstrom LM, Wendorf H, Myers DE, Irvin JD, Messinger Y, Ek O, Zeren T, Langlie MC, Evans WE, Uckun FM.

Clin Cancer Res. 1997 Jun;3(6):881-90.

11.

Prevalence and growth characteristics of malignant stem cells in B-lineage acute lymphoblastic leukemia.

Nishigaki H, Ito C, Manabe A, Kumagai M, Coustan-Smith E, Yanishevski Y, Behm FG, Raimondi SC, Pui CH, Campana D.

Blood. 1997 May 15;89(10):3735-44.

12.

Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys.

Uckun FM, Yanishevski Y, Tumer N, Waurzyniak B, Messinger Y, Chelstrom LM, Lisowski EA, Ek O, Zeren T, Wendorf H, Langlie MC, Irvin JD, Myers DE, Fuller GB, Evans W, Gunther R.

Clin Cancer Res. 1997 Mar;3(3):325-37.

13.

Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinoside.

Messinger Y, Yanishevski Y, Avramis VI, Ek O, Chelstrom LM, Gunther R, Myers DE, Irvin JD, Evans W, Uckun FM.

Clin Cancer Res. 1996 Sep;2(9):1533-42.

15.

Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase.

Krynetski EY, Krynetskaia NF, Yanishevski Y, Evans WE.

Mol Pharmacol. 1995 Jun;47(6):1141-7.

PMID:
7603453

Supplemental Content

Loading ...
Support Center